Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt 185.41
ZLTQ's Cash to Debt is ranked higher than
72% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. ZLTQ: 185.41 )
Ranked among companies with meaningful Cash to Debt only.
ZLTQ' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: 185.41 Max: No Debt
Current: 185.41
Equity to Asset 0.70
ZLTQ's Equity to Asset is ranked higher than
58% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ZLTQ: 0.70 )
Ranked among companies with meaningful Equity to Asset only.
ZLTQ' s Equity to Asset Range Over the Past 10 Years
Min: -9.69  Med: 0.70 Max: 0.89
Current: 0.7
-9.69
0.89
Interest Coverage N/A
ZLTQ's Interest Coverage is ranked higher than
74% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 53.44 vs. ZLTQ: N/A )
Ranked among companies with meaningful Interest Coverage only.
ZLTQ' s Interest Coverage Range Over the Past 10 Years
Min: N/A  Med: 9999.50 Max: 9999.99
Current: N/A
N/A
9999.99
F-Score: 6
Z-Score: 14.39
M-Score: -0.41
WACC vs ROIC
5.40%
105.99%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) 1.45
ZLTQ's Operating margin (%) is ranked lower than
51% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. ZLTQ: 1.45 )
Ranked among companies with meaningful Operating margin (%) only.
ZLTQ' s Operating margin (%) Range Over the Past 10 Years
Min: -1082.23  Med: -17.33 Max: 1.45
Current: 1.45
-1082.23
1.45
Net-margin (%) 16.37
ZLTQ's Net-margin (%) is ranked higher than
87% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. ZLTQ: 16.37 )
Ranked among companies with meaningful Net-margin (%) only.
ZLTQ' s Net-margin (%) Range Over the Past 10 Years
Min: -1111.78  Med: -17.29 Max: 16.37
Current: 16.37
-1111.78
16.37
ROE (%) 50.10
ZLTQ's ROE (%) is ranked higher than
98% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. ZLTQ: 50.10 )
Ranked among companies with meaningful ROE (%) only.
ZLTQ' s ROE (%) Range Over the Past 10 Years
Min: -299.73  Med: -28.57 Max: 42.91
Current: 50.1
-299.73
42.91
ROA (%) 32.85
ZLTQ's ROA (%) is ranked higher than
98% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: -0.71 vs. ZLTQ: 32.85 )
Ranked among companies with meaningful ROA (%) only.
ZLTQ' s ROA (%) Range Over the Past 10 Years
Min: -103.26  Med: -18.49 Max: 29.57
Current: 32.85
-103.26
29.57
ROC (Joel Greenblatt) (%) 18.10
ZLTQ's ROC (Joel Greenblatt) (%) is ranked higher than
69% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. ZLTQ: 18.10 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
ZLTQ' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -994.69  Med: -489.02 Max: 26.48
Current: 18.1
-994.69
26.48
Revenue Growth (3Y)(%) 41.90
ZLTQ's Revenue Growth (3Y)(%) is ranked higher than
97% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. ZLTQ: 41.90 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
ZLTQ' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.6  Med: -27.95 Max: 41.9
Current: 41.9
-68.6
41.9
» ZLTQ's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-05-05)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

ZLTQ Guru Trades in Q1 2015

Steven Cohen 1,150,721 sh (-11.48%)
Paul Tudor Jones 8,793 sh (-31.13%)
RS Investment Management 484,116 sh (-34.30%)
» More
Q2 2015

ZLTQ Guru Trades in Q2 2015

Joel Greenblatt 15,199 sh (New)
Jim Simons 115,600 sh (New)
RS Investment Management 704,066 sh (+45.43%)
Steven Cohen 1,407,000 sh (+22.27%)
Paul Tudor Jones 8,800 sh (+0.08%)
» More
Q3 2015

ZLTQ Guru Trades in Q3 2015

RS Investment Management 1,242,306 sh (+76.45%)
Steven Cohen 1,441,750 sh (+2.47%)
Joel Greenblatt Sold Out
Jim Simons Sold Out
Paul Tudor Jones Sold Out
» More
Q4 2015

ZLTQ Guru Trades in Q4 2015

Paul Tudor Jones 13,600 sh (New)
Jim Simons 103,850 sh (New)
Steven Cohen 2,319,887 sh (+60.91%)
RS Investment Management 1,181,996 sh (-4.85%)
» More
» Details

Insider Trades

Latest Guru Trades with ZLTQ

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 29.85
ZLTQ's P/E(ttm) is ranked lower than
59% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 26.66 vs. ZLTQ: 29.85 )
Ranked among companies with meaningful P/E(ttm) only.
ZLTQ' s P/E(ttm) Range Over the Past 10 Years
Min: 19.07  Med: 230.66 Max: 1567.27
Current: 29.85
19.07
1567.27
Forward P/E 55.25
ZLTQ's Forward P/E is ranked lower than
98% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 18.69 vs. ZLTQ: 55.25 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 29.85
ZLTQ's PE(NRI) is ranked lower than
57% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 26.94 vs. ZLTQ: 29.85 )
Ranked among companies with meaningful PE(NRI) only.
ZLTQ' s PE(NRI) Range Over the Past 10 Years
Min: 19.07  Med: 234.50 Max: 1724
Current: 29.85
19.07
1724
Price/Owner Earnings (ttm) 28.12
ZLTQ's Price/Owner Earnings (ttm) is ranked higher than
56% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 30.78 vs. ZLTQ: 28.12 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
ZLTQ' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 17.95  Med: 110.80 Max: 256.76
Current: 28.12
17.95
256.76
P/B 9.55
ZLTQ's P/B is ranked lower than
92% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. ZLTQ: 9.55 )
Ranked among companies with meaningful P/B only.
ZLTQ' s P/B Range Over the Past 10 Years
Min: 1.79  Med: 9.01 Max: 19.15
Current: 9.55
1.79
19.15
P/S 4.76
ZLTQ's P/S is ranked lower than
66% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. ZLTQ: 4.76 )
Ranked among companies with meaningful P/S only.
ZLTQ' s P/S Range Over the Past 10 Years
Min: 0.16  Med: 4.16 Max: 7.94
Current: 4.76
0.16
7.94
PFCF 386.43
ZLTQ's PFCF is ranked lower than
100% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. ZLTQ: 386.43 )
Ranked among companies with meaningful PFCF only.
ZLTQ' s PFCF Range Over the Past 10 Years
Min: 82.3  Med: 203.83 Max: 397.59
Current: 386.43
82.3
397.59
POCF 165.63
ZLTQ's POCF is ranked lower than
100% of the 131 Companies
in the Global Medical Devices industry.

( Industry Median: 21.24 vs. ZLTQ: 165.63 )
Ranked among companies with meaningful POCF only.
ZLTQ' s POCF Range Over the Past 10 Years
Min: 68.75  Med: 133.78 Max: 170.39
Current: 165.63
68.75
170.39
EV-to-EBIT 307.74
ZLTQ's EV-to-EBIT is ranked lower than
98% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: 21.14 vs. ZLTQ: 307.74 )
Ranked among companies with meaningful EV-to-EBIT only.
ZLTQ' s EV-to-EBIT Range Over the Past 10 Years
Min: -231.8  Med: -4.40 Max: 644.5
Current: 307.74
-231.8
644.5
EV-to-EBITDA 185.80
ZLTQ's EV-to-EBITDA is ranked lower than
97% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.32 vs. ZLTQ: 185.80 )
Ranked among companies with meaningful EV-to-EBITDA only.
ZLTQ' s EV-to-EBITDA Range Over the Past 10 Years
Min: -372.2  Med: -4.60 Max: 346.7
Current: 185.8
-372.2
346.7
Current Ratio 2.28
ZLTQ's Current Ratio is ranked lower than
59% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. ZLTQ: 2.28 )
Ranked among companies with meaningful Current Ratio only.
ZLTQ' s Current Ratio Range Over the Past 10 Years
Min: 0.63  Med: 2.68 Max: 8.23
Current: 2.28
0.63
8.23
Quick Ratio 1.75
ZLTQ's Quick Ratio is ranked lower than
58% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. ZLTQ: 1.75 )
Ranked among companies with meaningful Quick Ratio only.
ZLTQ' s Quick Ratio Range Over the Past 10 Years
Min: 0.52  Med: 2.26 Max: 7.85
Current: 1.75
0.52
7.85
Days Inventory 106.14
ZLTQ's Days Inventory is ranked higher than
64% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 136.13 vs. ZLTQ: 106.14 )
Ranked among companies with meaningful Days Inventory only.
ZLTQ' s Days Inventory Range Over the Past 10 Years
Min: 46.43  Med: 95.09 Max: 109.81
Current: 106.14
46.43
109.81
Days Sales Outstanding 47.67
ZLTQ's Days Sales Outstanding is ranked higher than
78% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 70.17 vs. ZLTQ: 47.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
ZLTQ' s Days Sales Outstanding Range Over the Past 10 Years
Min: 8.79  Med: 34.17 Max: 237.12
Current: 47.67
8.79
237.12
Days Payable 53.51
ZLTQ's Days Payable is ranked lower than
57% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 62.81 vs. ZLTQ: 53.51 )
Ranked among companies with meaningful Days Payable only.
ZLTQ' s Days Payable Range Over the Past 10 Years
Min: 42.46  Med: 56.79 Max: 144.83
Current: 53.51
42.46
144.83

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 17.52
ZLTQ's Price/Net Current Asset Value is ranked lower than
82% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 6.20 vs. ZLTQ: 17.52 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
ZLTQ' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 3.36  Med: 16.59 Max: 19.12
Current: 17.52
3.36
19.12
Price/Tangible Book 9.91
ZLTQ's Price/Tangible Book is ranked lower than
82% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 3.89 vs. ZLTQ: 9.91 )
Ranked among companies with meaningful Price/Tangible Book only.
ZLTQ' s Price/Tangible Book Range Over the Past 10 Years
Min: 2.54  Med: 9.38 Max: 16.44
Current: 9.91
2.54
16.44
Price/Projected FCF 430.57
ZLTQ's Price/Projected FCF is ranked lower than
99% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. ZLTQ: 430.57 )
Ranked among companies with meaningful Price/Projected FCF only.
ZLTQ' s Price/Projected FCF Range Over the Past 10 Years
Min: 407.57  Med: 407.57 Max: 407.57
Current: 430.57
Price/Median PS Value 1.15
ZLTQ's Price/Median PS Value is ranked lower than
59% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. ZLTQ: 1.15 )
Ranked among companies with meaningful Price/Median PS Value only.
ZLTQ' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.09  Med: 1.09 Max: 1.55
Current: 1.15
0.09
1.55
Price/Graham Number 3.63
ZLTQ's Price/Graham Number is ranked lower than
72% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 2.14 vs. ZLTQ: 3.63 )
Ranked among companies with meaningful Price/Graham Number only.
ZLTQ' s Price/Graham Number Range Over the Past 10 Years
Min: 3.41  Med: 13.43 Max: 23.45
Current: 3.63
3.41
23.45
Earnings Yield (Greenblatt) (%) 0.31
ZLTQ's Earnings Yield (Greenblatt) (%) is ranked lower than
51% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. ZLTQ: 0.31 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
ZLTQ' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.2  Med: 0.40 Max: 299
Current: 0.31
0.2
299

More Statistics

Revenue(Mil) $255
EPS $ 1.01
Beta0.47
Short Percentage of Float21.52%
52-Week Range $18.41 - 38.49
Shares Outstanding(Mil)39.31

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 315 377 417
EPS($) 0.16 0.56 0.78
EPS without NRI($) 0.16 0.56 0.78

Business Description

Industry: Medical Devices » Medical Devices
Compare:OISE:OSSRu, XSWX:TECN, NYSE:PEN, OCSE:AMBU B, SHSE:600587, SZSE:300238 » details
ZELTIQ Aesthetics Inc was incorporated in the state of Delaware on March 22, 2005. In August 2011, the Company incorporated ZELTIQ Limited as a wholly-owned subsidiary in the United Kingdom to serve as its sales office for direct sales in Europe. The Company was founded to develop and commercialize a non-invasive product for the selective reduction of fat. On October 24, 2011, the Company completed its initial public offering, or IPO, of 8,050,000 shares of common stock, of which 7,743,000 shares were sold by the Company and 307,000 shares were sold by existing stockholders. The Company generates revenue from sales of CoolSculpting system and from sales of consumables to its customers. Its geographical region includes North America and International. The Company's first commercial product, the CoolSculpting system, is designed to selectively reduce stubborn fat bulges. CoolSculpting is based on the scientific principle that fat cells are more sensitive to cold than the overlying skin and surrounding tissues. The Company manufactures and distributes its CoolSculpting system, including procedure packs, at its Dublin facility. The Livermore facility is used primarily for raw material storage. Through 2012 and the beginning of 2013, the Company has utilized OnCore Manufacturing LLC to manufacture and supply CoolSculpting system. ZELTIQ, CoolSculpting, and Company's logo are registered trademarks in the United States and in certain foreign countries. The design, development, manufacture, testing and sale of products are subject to regulation by governmental authorities, mainly FDA, and corresponding state and foreign regulatory agencies.
» More Articles for ZLTQ

Headlines

Articles On GuruFocus.com
Steven Cohen's Newest Buys, Additions and Reductions Mar 04 2015 
Steven Cohen Buys New Drug Stock, Triples Investment in Medical Company Jan 25 2015 
4 Stocks To Buy, 1 To Avoid In 2012 Feb 18 2012 
Weekly CFO Sales Highlight: INFA, DHR, AN, SMTC, ZLTQ Oct 31 2011 

More From Other Websites
ZELTIQ AESTHETICS INC Files SEC form 8-K, Change in Directors or Principal Officers Apr 26 2016
Hospira President, David J. Endicott, Joins ZELTIQ Aesthetics Board of Directors Apr 26 2016
Hospira President, David J. Endicott, Joins ZELTIQ Aesthetics Board of Directors Apr 26 2016
ZELTIQ Announces Conference Call and Webcast of First Quarter 2016 Financial Results to Be Held on... Apr 18 2016
ZELTIQ Announces Conference Call and Webcast of First Quarter 2016 Financial Results to Be Held on... Apr 18 2016
Coverage initiated on ZELTIQ Aesthetics by Brean Capital Apr 13 2016
Award-Winning CoolSculpting(R) Procedure Now FDA-Cleared to Reduce Fat Around Bra Straps, on the... Apr 05 2016
ETF’s with exposure to ZELTIQ Aesthetics, Inc. : March 29, 2016 Mar 29 2016
ETF’s with exposure to ZELTIQ Aesthetics, Inc. : March 18, 2016 Mar 18 2016
ZELTIQ AESTHETICS INC Financials Mar 18 2016
ZELTIQ AESTHETICS INC Files SEC form 10-K, Annual Report Mar 15 2016
ZELTIQ to Present at the 28th Annual ROTH Conference Mar 09 2016
ZELTIQ Aesthetics, Inc. :ZLTQ-US: Earnings Analysis: Q4, 2015 By the Numbers Mar 03 2016
ZELTIQ(R) Launches 3-in-1 CoolAdvantage(TM) Applicator for the CoolSculpting(R) System at American... Mar 03 2016
Edited Transcript of ZLTQ earnings conference call or presentation 29-Feb-16 9:30pm GMT Feb 29 2016
ZELTIQ AESTHETICS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Feb 29 2016
Zeltiq misses 4Q profit forecasts Feb 29 2016
Zeltiq misses 4Q profit forecasts Feb 29 2016
ZELTIQ Announces Fourth Quarter and Full Year 2015 Financial Results Feb 29 2016
ZELTIQ Announces Chief Financial Officer Transition Feb 29 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK